
Leqembi’s Real Advantage Isn’t the Drug — It’s the Network
The diagnostic and treatment network behind Leqembi may be its biggest competitive edge.

The diagnostic and treatment network behind Leqembi may be its biggest competitive edge.

Swedish researchers find that cholinesterase inhibitors provide cognitive benefits and reduce mortality for up to five years after an Alzheimer’s diagnosis. One medication significantly reduced the risk of developing severe dementia.

New research reveals that Leqembi’s Fc region switches on microglia — the brain’s immune cells — helping them clear toxic amyloid. Here’s why that mechanism matters for treatment and safety.

A safer Alzheimer’s treatment may be on the horizon — but families still have meaningful choices today.

Many diagnosed patients won’t qualify — here are the
7 medical criteria.

New early-onset Alzheimer’s data show that lecanemab can slow functional decline—even while tau continues to spread in the brain. The research helps explain how amyloid-lowering treatments may still preserve daily life, despite the disease’s complexity.

In a one-hour seminar, a leading neurologist answers the most important questions families ask about what these new therapies can realistically deliver — from effectiveness and safety to eligibility, infusion logistics, cost, and access.

New evidence suggests genetics—not geography—may explain why Leqembi causes fewer ARIA brain side effects in parts of Asia, and what that means for families everywhere.

Alzheimer’s treatment eligibility may be far larger than previously thought. A major Nature study using blood tests suggests millions more older adults could qualify for treatment than current use reflects. As diagnosis becomes easier, demand for drugs like Leqembi could shift sharply.

New studies highlight smoother tolerability, easier routines, and practical safety updates that make the rivastigmine patch an increasingly caregiver-friendly option.

Teepa shows how to make the most from the ability to communicate with dementia. Watch now.

HEALTH VIDEO (TED TALK): What keeps brains healthy and minds happy? Dr. Robert Waldinger is directing a rare study, in its 75th year, to find out. Watch him share 3 lessons learned. See good science verify practical wisdom on healthy living.

PREVENTION VIDEOS: Learn secrets to grow old gracefully, with little dementia, from centenarians on the Greek island of Ikaria.

Three important dementia studies focus on HS-AGING, a type of dementia almost as common as Alzheimer’s in the 85+ group. Yet few people have heard of it. Why? What makes it different?

An intriguing study of 120 grandmothers might surprise you. Doctors know socially engaged people have better cognition and less dementia. But can a person get too much of a good thing? What’s the right balance?

Enjoy this great duet between a musician with dementia and his son. A triumph of spirit over Alzheimer’s! Sing-a-long if you like!

It looks like a sneeze cannot give anyone Alzheimer’s. While Alzheimer’s abnormal disease proteins do spread from cell-to-cell, they are not “infectious”. Check out the facts.
No spam, only news and updates.



We use cookies and similar technologies to improve your experience, understand how our content is used, and support relevant advertising that helps keep Alzheimer’s Weekly free to readers. You can choose to accept, deny, or manage your preferences at any time. Declining certain cookies may affect features such as embedded videos, comments, and personalized advertising.